Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy

Michelle S. Chen, Lauren E. Howard, Shannon Stock, Anna Dolgner, Stephen J. Freedland, William Aronson, Martha Terris, Zachary Klaassen, Christopher Kane, Christopher Amling, Matthew Cooperberg, Timothy J. Daskivich

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


Purpose: Accurate prediction of competing risks of mortality remains a key component of prostate cancer treatment decision-making. We sought to validate the Prostate Cancer Comorbidity Index (PCCI) score for predicting other-cause mortality (OCM) and cancer outcomes in men undergoing radical prostatectomy (RP). Materials and methods: We sampled 4857 men with prostate cancer treated with RP in the VA from 2000–2018. Risks of OCM, 90-day all-cause mortality (ACM), prostate cancer-specific mortality, metastasis, and biochemical recurrence by PCCI score were assessed using Cox proportional hazards and logistic regression. We compared prediction of 90-day ACM between PCCI and the American Society of Anesthesiology (ASA) score, a validated predictor of short-term mortality. Results: Over median follow-up of 6.7 years (IQR 3.7–10.3), there was a stepwise increase in risk of OCM with higher PCCI score, with hazards (95%CI) of 1.53 (1.14–2.04), 2.11 (1.55–2.88), 2.36 (1.68–3.31), 3.61 (2.61–4.98), and 4.99 (3.58–6.96) for PCCI 1-2, 3-4, 5-6, 7-9, and 10 + (vs. 0), respectively. Projected 10-year cumulative incidence of OCM was 8%, 12%, 16%, 19%, 26%, and 32% for scores of 0, 1-2, 3-4, 5-6, 7-9, and 10+ , respectively. Men with PCCI 7+ had greater odds of 90-day ACM (OR 3.48, 95%CI 1.26–9.63) while men with higher ASA did not. Higher PCCI score was associated with worse cancer outcomes, with the highest categories driving the associations. Conclusions: The PCCI is a robust measure of short- and long-term OCM after RP, validated for use in clinical care and health services research focusing on surgical patient populations.

Original languageEnglish (US)
Pages (from-to)715-721
Number of pages7
JournalProstate Cancer and Prostatic Diseases
Issue number4
StatePublished - Dec 2023

ASJC Scopus subject areas

  • Oncology
  • Urology
  • Cancer Research


Dive into the research topics of 'Validation of the prostate cancer comorbidity index in predicting cause-specific mortality in men undergoing radical prostatectomy'. Together they form a unique fingerprint.

Cite this